
Indias Rank In 2025 Human Development Index Improves, Climbs To...; Life Expectancy Rises To...
New Delhi: India continues its steady rise on the Human Development Index (HDI), ranking 130th out of 193 countries in the 2025 Human Development Report (HDR) released today by the United Nations Development Programme. With an HDI value increasing from 0.676 in 2022 to 0.685 in 2023, India remains in the medium human development category, moving closer to the threshold for high human development (HDI ≥ 0.700).
The 2025 HDR, titled "A Matter of Choice: People and Possibilities in the Age of AI," highlights the critical role of artificial intelligence in shaping the next chapter of human development—particularly in fast-growing economies like India.
"We congratulate India on its notable progress in the Human Development Index, rising from rank 133 in 2022 to 130 in 2023. This advancement reflects sustained improvements in key dimensions of human development, particularly in mean years of schooling and national income per capita. India's life expectancy reaching its highest level since the inception of the index is a testament to the country's robust recovery from the pandemic and its investments and commitment to long-term human well-being. With a renewed focus on women-led development, quality education, and healthcare for all, India is well-positioned to achieve inclusive growth and continued progress on human development," said Angela Lusigi, Resident Representative, UNDP India.
India's HDI Value Increased
India's HDI value has increased by over 53 percent since 1990, growing faster than both the global and South Asian averages. This progress has been fueled by economic growth and targeted social protection and welfare programs.
Life Expectancy Rose To 72 Years
Life expectancy rose from 58.6 years in 1990 to 72 years in 2023, the highest recorded since the index began. National health programs by successive governments, such as the National Rural Health Mission, Ayushman Bharat, Janani Suraksha Yojana, and Poshan Abhiyaan, have contributed significantly to this achievement.
Children today are expected to stay in school for 13 years on average, up from 8.2 years in 1990. Initiatives like the Right to Education Act, Samagra Shiksha Abhiyan, and the National Education Policy 2020 have enhanced outcomes. However, quality and learning outcomes remain areas for continued focus.
On the economic front, India's Gross National Income per capita rose more than four times, from USD 2,167.22 (1990) to USD 9,046.76 (2023). Over the years, India's progress on economic growth and investments in programs like MGNREGA, Jan Dhan Yojana, and digital inclusion have contributed to poverty reduction. Importantly, 135 million Indians escaped multidimensional poverty between 2015-16 and 2019-21.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
an hour ago
- Business Standard
Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore
Global investment firm Carlyle group on Wednesday exited Indegene by divesting its entire 10.2 per cent stake in digital healthcare services for Rs 1,447 crore through open market transactions. According to the bulk deal data available on the NSE, US-based Carlyle group, through its arm CA Dawn Investments, sold more than 2.44 crore shares, amounting to a 10.20 per cent stake in Indegene. The shares were offloaded in the price range of Rs 591.02-591.84 apiece, taking the combined transaction value to Rs 1,447.17 crore. Meanwhile, Premji Invest's affiliate PI Opportunities AIF V, Capital group, Societe Generale, Luxembourg-based Eastbridge Group and Abakkus Asset Manager cumulatively bought 1.06 crore shares or 4.42 per cent stake in Indegene for Rs 627 crore. The shares were picked up in the price range of Rs 591-591.48 apiece, taking the aggregate deal value to Rs 626.85 crore. Details of the other buyers of Indegene's shares could not be ascertained on the National Stock Exchange (NSE). Shares of Indegene declined 4.07 per cent to close at Rs 594.50 per piece on the NSE. PE firm Carlyle group's clocked an impressive 31 per cent internal rate of return over a four-year period. This highly profitable divestment marks a pivotal moment, underscoring the immense potential of India's digital healthcare sector. In April 2021, Carlyle invested USD 122 million (Rs 917 crore) in Indegene by acquiring 45.5 million shares at Rs 201 each on the stock exchanges. Carlyle executed a phased exit as Indegene scaled its global operations and went public in May 2024. The shares were sold by the PE firm at Rs 452 apiece during the initial public offering, at Rs 618 per share in December 2024, and the final tranche at about Rs 591 each in June 2025, enabling Carlyle to secure significant returns amidst varying market conditions.


Economic Times
2 hours ago
- Economic Times
Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore
Global investment firm Carlyle group on Wednesday exited Indegene by divesting its entire 10.2 per cent stake in digital healthcare services for Rs 1,447 crore through open market transactions. ADVERTISEMENT According to the bulk deal data available on the NSE, US-based Carlyle group, through its arm CA Dawn Investments, sold more than 2.44 crore shares, amounting to a 10.20 per cent stake in Indegene. The shares were offloaded in the price range of Rs 591.02-591.84 apiece, taking the combined transaction value to Rs 1,447.17 crore. Meanwhile, Premji Invest's affiliate PI Opportunities AIF V, Capital group, Societe Generale, Luxembourg-based Eastbridge Group and Abakkus Asset Manager cumulatively bought 1.06 crore shares or 4.42 per cent stake in Indegene for Rs 627 crore. The shares were picked up in the price range of Rs 591-591.48 apiece, taking the aggregate deal value to Rs 626.85 crore. Details of the other buyers of Indegene's shares could not be ascertained on the National Stock Exchange (NSE). ADVERTISEMENT Shares of Indegene declined 4.07 per cent to close at Rs 594.50 per piece on the NSE. PE firm Carlyle group's clocked an impressive 31 per cent internal rate of return over a four-year period. This highly profitable divestment marks a pivotal moment, underscoring the immense potential of India's digital healthcare sector. ADVERTISEMENT In April 2021, Carlyle invested USD 122 million (Rs 917 crore) in Indegene by acquiring 45.5 million shares at Rs 201 each on the stock exchanges. Carlyle executed a phased exit as Indegene scaled its global operations and went public in May 2024. The shares were sold by the PE firm at Rs 452 apiece during the initial public offering, at Rs 618 per share in December 2024, and the final tranche at about Rs 591 each in June 2025, enabling Carlyle to secure significant returns amidst varying market conditions. (You can now subscribe to our ETMarkets WhatsApp channel)


Time of India
2 hours ago
- Time of India
Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore
Global investment firm Carlyle group on Wednesday exited Indegene by divesting its entire 10.2 per cent stake in digital healthcare services for Rs 1,447 crore through open market transactions. According to the bulk deal data available on the NSE, US-based Carlyle group, through its arm CA Dawn Investments, sold more than 2.44 crore shares , amounting to a 10.20 per cent stake in Indegene. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like コンピュータでゲームをするのが好きなら、この新しいアドベンチャーゲームは必ずプレイすべきです。 アドベンチャーゲーム ゲームをプレイ Undo The shares were offloaded in the price range of Rs 591.02-591.84 apiece, taking the combined transaction value to Rs 1,447.17 crore. Play Video Pause Skip Backward Skip Forward Unmute Current Time 0:00 / Duration 0:00 Loaded : 0.00% 0:00 Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 1x Playback Rate Chapters Chapters Descriptions descriptions off , selected Captions captions settings , opens captions settings dialog captions off , selected Audio Track default , selected Picture-in-Picture Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Text Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Transparent Caption Area Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Drop shadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Meanwhile, Premji Invest's affiliate PI Opportunities AIF V, Capital group, Societe Generale, Luxembourg-based Eastbridge Group and Abakkus Asset Manager cumulatively bought 1.06 crore shares or 4.42 per cent stake in Indegene for Rs 627 crore. The shares were picked up in the price range of Rs 591-591.48 apiece, taking the aggregate deal value to Rs 626.85 crore. Live Events Details of the other buyers of Indegene's shares could not be ascertained on the National Stock Exchange (NSE). Shares of Indegene declined 4.07 per cent to close at Rs 594.50 per piece on the NSE. PE firm Carlyle group's clocked an impressive 31 per cent internal rate of return over a four-year period. This highly profitable divestment marks a pivotal moment, underscoring the immense potential of India's digital healthcare sector. In April 2021, Carlyle invested USD 122 million (Rs 917 crore) in Indegene by acquiring 45.5 million shares at Rs 201 each on the stock exchanges. Carlyle executed a phased exit as Indegene scaled its global operations and went public in May 2024. The shares were sold by the PE firm at Rs 452 apiece during the initial public offering, at Rs 618 per share in December 2024, and the final tranche at about Rs 591 each in June 2025, enabling Carlyle to secure significant returns amidst varying market conditions.